She's Not Allergic to Her Food. She's Fermenting It. | The Angry Gut, Chapter 31

Low dose naltrexone · mechanism of action

Low Dose Naltrexone Mechanism of Action: Four Links, Each With a Tier

Low dose naltrexone works indirectly, through a chain of four links: a rebound rise in beta-endorphin, intermittent rather than continuous receptor blockade, effects on lymphocytes and regulatory T cells, and antagonism of Toll-like receptor 4. It is not a mast cell stabilizer.

The low-dose naltrexone mechanism most often repeated is the one the pharmacology does not support. The one that survives is indirect, upstream, and graded link by link.

Ask ten clinicians for the low dose naltrexone mechanism of action and several will call it a mast cell stabilizer. It is not, and the error matters because it sets the wrong expectations and the wrong endpoints. The mechanism that holds up is a chain of four links, each resting on a different grade of evidence.

The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes applies that chain, in the chapter video She’s Not Allergic to Her Food. She’s Fermenting It., to a patient with gut-predominant mast cell symptoms. Measura [Cardiometabolic and Autonomic Health Analysis] reports objective measurements to the clinician who orders them and neither diagnoses, treats nor prescribes. The pharmacology below is for interpretation and co-management, not a recommendation to start or change any drug.

Link one: the rebound, measured in human CSF

The therapeutic event is the rebound, not the blockade. At a standard rather than low dose, naltrexone raised cerebrospinal fluid beta-endorphin from 1.15 to 2.03 fmol/mL while POMC did not move, so the beta-endorphin-to-POMC ratio rose 80%, holding after two and seven days. Two details inside that study bear on patient selection. Among fourteen healthy volunteers, overweight and obese subjects showed a 138% increase versus 52.1% for the lean group, so the metabolically loaded patient may mount the larger response. And plasma cortisol rose from 12.4 to 15.6 µg/dL, a 28% increase. A drug that lifts endorphin and cortisol together is not a clean intervention.

Link two: duration of blockade, not dose

Three decades of laboratory work converge on one principle: intermittent blockade at low doses depressed cell replication, while continuous blockade at high doses enhanced it. The full 100 mg dose occupies 92% of kappa receptors on PET, and in that alcohol-use cohort higher occupancy went with more craving, not less. Occupancy in the 1.5 to 4.5 mg range has never been imaged in humans. The main metabolite, 6beta-naltrexol, is itself an antagonist with a terminal half-life of 11.1 hours, so whether a bedtime dose is still intermittent by morning is unmeasured. That is the gap in the dose rationale, stated plainly.

Link three: lymphocytes and Tregs

Of the four, this link carries the weakest evidence. Whether immune cells express opioid receptors is contested, with some groups confirming mRNA and protein and others finding no message. In female mice, regulatory T cells produced enkephalin that engaged sensory-neuron delta opioid receptors and dampened nociception, a function separable from immunosuppression and dependent on sex hormones. Tregs and the opioid system are coupled; the direction of traffic in humans is not established. The widely quoted sentence that endorphins bind Tregs to reduce cytokines traces to a single case report in which one patient received naltrexone, immunoglobulin and antibiotics together.

Human data are limited to downstream output. Following an eight-week course in eight women with fibromyalgia, eighteen plasma mediators fell, including IL-1β, IL-6, IL-17A and TNF-α, with pain down 15%. Anti-inflammatory mediators such as IL-10 fell too, and no multiplicity correction was described. It is a signal, not a clean anti-inflammatory effect.

Link four: TLR4, stated narrowly

Naltrexone and naloxone antagonize Toll-like receptor 4, the lipopolysaccharide receptor. In the defining experiment all four isomers, including the clinical (−)-naltrexone, attenuated LPS-induced signaling in a cell line by non-competitive inhibition, but the microglial and animal work used the (+)-isomers and (−)-naloxone. Naltrexone shows no stereoselectivity at TLR4, which is why the clinical isomer works at all, and it is weak, roughly 25 times less potent than an optimized bivalent ligand. The (+)-isomers inhibited nitric oxide and TNF-α but not IL-1β, and not NF-κB, p38 or JNK signaling; the blocked arm was TRIF-IRF3-interferon. No human study has shown low-dose naltrexone antagonizing TLR4. The tier is cellular and animal.

MRGPRX2: why it is not a stabilizer

Opioids degranulate mast cells through MRGPRX2, outside the classical opioid system. Naltrexone is inactive there, neither agonist nor antagonist, and naloxone at 10 µM did not alter opioid-induced degranulation in a human mast cell line. In the animal spinal mass model, scores were 2.3 with morphine and 2.5 with morphine plus naltrexone, while cromolyn blocked the damage. None of that contradicts the chain above. The route is indirect and upstream: endorphin rebound acting on the lymphocyte compartment, and TLR4 antagonism thinning the cytokine traffic that keeps mucosal mast cells primed. Quieting follows without the drug touching the mast cell membrane.

Low dose naltrexone mechanism of action in the clinical record

Crohn’s disease, randomized: two trials, 46 participants. Remission 30% against 18%, not significant; 70-point response 83% against 38%, significant; endoscopic response 72% against 25%. GRADE low for imprecision.
Fibromyalgia, randomized: four trials, 222 patients, pooled pain reduction of −0.86 points; the largest trial, 6 mg for twelve weeks, missed its primary endpoint.
IBS: open-label only, 0.5 mg daily, global improvement in 76% of 42 patients.
Practice-level data: a survey of 553 patients rated benefit 5.6 of 10, equal to benzodiazepines and below antihistamines at 6.3; a dysautonomia chart review found no significant change on a validated autonomic instrument, with pain improvement documented in 24.14%.

Where objective measurement fits

Tryptase, histamine and mast cell testing are specialized studies done elsewhere; Measura does not run them beyond general laboratory panels. Under the restrictive consensus, normal serum tryptase is 0 to 11.4 ng/mL and an episode is defined by tryptase exceeding 1.2 times baseline plus 2 ng/mL, and every one of the three criteria is required.

What Measura can document is the comorbid terrain. Orthostatic intolerance was the prescribing reason in 27.78% of that dysautonomia review, and the null there was on a questionnaire. Two biological drivers keep this population primed, endotoxin crossing a damaged barrier and metaflammation in the first brain, and one structural one: every comorbidity is an exclusion criterion somewhere, so the trial population never matches the clinic. Objective baselines help close that gap:

Autonomic nervous system testing and cardiac autonomic reflex tests document orthostatic and reflex responses before and during any therapy the treating physician chooses.
Heart rate variability records vagal tone as a repeatable number.
Bioimpedance body composition characterizes adiposity, relevant given the larger rebound seen in overweight and obese subjects.

Selection and ordering are covered under clinical selection criteria and specialty applications. The patient version of this topic is here, the autonomic overlap is developed in orthostatic intolerance screening, and the study-level limits are in the Chapter 31 Deep Dive.

Frequently asked questions

Does naltrexone act directly on mast cells?

Not through the pathway that matters for opioid-driven degranulation. Naltrexone is inactive at MRGPRX2, and naloxone did not alter opioid-induced degranulation in a human mast cell line. Any effect on mast cell activity is indirect, through endorphin rebound on lymphocytes and TLR4 antagonism reducing upstream cytokine priming. Cromolyn remains the membrane stabilizer. Read the clinical rationale for the protocol.

Why would a low dose work differently from a full dose?

The laboratory literature points to duration of receptor blockade rather than dose: intermittent blockade depressed cell replication and continuous blockade enhanced it. The full 100 mg dose occupies 92% of kappa receptors, but occupancy at 1.5 to 4.5 mg has never been measured in humans, and the active metabolite’s 11.1-hour half-life complicates the intermittency assumption. See answers to common physician questions.

Is the TLR4 effect established in patients?

No. TLR4 antagonism by naltrexone rests on cell-line and animal work, with non-competitive inhibition and no stereoselectivity. The narrower finding is that the isomers tested inhibited TNF-α and nitric oxide but not IL-1β. No human study has shown low-dose naltrexone antagonizing TLR4, so it should be documented as mechanism tier. See how Measura results are reported.

Which patients with mast cell symptoms merit autonomic testing?

Patients reporting lightheadedness or tachycardia on standing, those with hypermobility or a dysautonomia label, and anyone in whom a treating physician wants an objective baseline rather than a questionnaire. Autonomic findings document comorbid physiology; they neither confirm nor exclude mast cell activation, which requires tryptase-based criteria done elsewhere. Review standing orders for screening.

How should mechanism tiers be documented in the chart?

Record the diagnostic criteria set used, paired tryptase values if obtained elsewhere, objective autonomic and body composition baselines, and a planned re-measure date. Stating which claims are established, mechanistic or practice-based keeps later interpretation honest and supports structured quality documentation without implying a diagnosis the testing does not make. See how results reach the record.

See how autonomic baselines fit a complex-patient workflow

Learn how Measura autonomic, heart rate variability and body composition testing can document the comorbid terrain in patients under evaluation for mast cell activation.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Gordon, R. J., Panigrahi, S. K., Meece, K., Atalayer, D., Smiley, R., & Wardlaw, S. L. (2017). Effects of opioid antagonism on cerebrospinal fluid melanocortin peptides and cortisol levels in humans. Journal of the Endocrine Society, 1(10), 1235-1246. https://doi.org/10.1210/js.2017-00289
McLaughlin, P. J., & Zagon, I. S. (2015). Duration of opioid receptor blockade determines biotherapeutic response. Biochemical Pharmacology, 97(3), 236-246. https://doi.org/10.1016/j.bcp.2015.06.016
de Laat, B., Nabulsi, N., Huang, Y., O’Malley, S. S., Froehlich, J. C., Morris, E. D., & Krishnan-Sarin, S. (2020). Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. Molecular Psychiatry, 26(9), 5053-5060. https://doi.org/10.1038/s41380-020-0811-8
Midavaine, E., Moraes, B. C., Benitez, J., Rodriguez, S. R., Braz, J. M., Kochhar, N. P., Eckalbar, W. L., Tian, L., Domingos, A. I., Pintar, J. E., Basbaum, A. I., & Kashem, S. W. (2025). Meningeal regulatory T cells inhibit nociception in female mice. Science, 388(6742), 96-104. https://doi.org/10.1126/science.adq6531
Parkitny, L., & Younger, J. (2017). Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines, 5(2), 16. https://doi.org/10.3390/biomedicines5020016
Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). The European Journal of Neuroscience, 28(1), 20-29. https://doi.org/10.1111/j.1460-9568.2008.06321.x
Wang, X., Zhang, Y., Peng, Y., Hutchinson, M. R., Rice, K. C., Yin, H., & Watkins, L. R. (2016). Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. British Journal of Pharmacology, 173(5), 856-869. https://doi.org/10.1111/bph.13394
Lansu, K., Karpiak, J., Liu, J., Huang, X.-P., McCorvy, J. D., Kroeze, W. K., Che, T., Nagase, H., Carroll, F. I., Jin, J., Shoichet, B. K., & Roth, B. L. (2017). In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nature Chemical Biology, 13(5), 529-536. https://doi.org/10.1038/nchembio.2334
Parker, C. E., Nguyen, T. M., Segal, D., MacDonald, J. K., & Chande, N. (2018). Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews, 4(4), CD010410. https://doi.org/10.1002/14651858.CD010410.pub3
Zapata, N., Georgiadi, E., Cantrell, C., Rilinger, R. G., Levine, M. A., & Wilson, R. (2025). Low-dose naltrexone for managing pain and autonomic symptoms in patients with dysautonomia. Cureus, 17(6), e86538. https://doi.org/10.7759/cureus.86538